| | Publication Year | Title | Author(s) |
| 1 | 10-Nov-2014 | Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. | Shi, Qian; de Gramont, Aimery; Grothey, Axel; Zalcberg, John; Chibaudel, Benoist; Schmoll, Hans-Joachim; Seymour, Matthew T; Adams, Richard A; Saltz, Leonard; Goldberg, Richard M; Punt, Cornelis J A; Douillard, Jean-Yves; Hoff, Paulo M; Hecht, Joel Randolph; Hurwitz, Herbert; Díaz-Rubio, Eduardo; Porschen, Rainer; Tebbutt, Niall C ; Fuchs, Charles; Souglakos, John; Falcone, Alfredo; Tournigand, Christophe; Kabbinavar, Fairooz F; Heinemann, Volker; Van Cutsem, Eric; Bokemeyer, Carsten; Buyse, Marc; Sargent, Daniel J |
| 2 | 12-Dec-2013 | Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. | Jonker, D J; Karapetis, C S; Harbison, C; O'Callaghan, Christopher J ; Tu, D; Simes, R J; Malone, D P; Langer, C; Tebbutt, Niall C ; Price, Timothy J; Shapiro, J; Siu, L L; Wong, R P W; Bjarnason, G; Moore, M J; Zalcberg, John R; Khambata-Ford, S |
| 3 | 16-Sep-2013 | Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Ohtsu, Atsushi; Ajani, Jaffer A; Bai, Yu-Xian; Bang, Yung-Jue; Chung, Hyun-Cheol; Pan, Hong-Ming; Sahmoud, Tarek; Shen, Lin; Yeh, Kun-Huei; Chin, Keisho; Muro, Kei; Kim, Yeul Hong; Ferry, David; Tebbutt, Niall C ; Al-Batran, Salah-Eddin; Smith, Heind; Costantini, Chiara; Rizvi, Syed; Lebwohl, David; Van Cutsem, Eric |
| 4 | 14-Feb-2013 | Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. | Tebbutt, Niall C ; Parry, M M; Zannino, D; Strickland, A H; Van Hazel, G A; Pavlakis, N; Ganju, V; Mellor, D; Dobrovic, Alexander ; Gebski, V J |
| 5 | 27-Jan-2011 | Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. | Tebbutt, Niall C ; Murphy, F; Zannino, D; Wilson, K; Cummins, M M; Abdi, E; Strickland, A H; Lowenthal, R M; Marx, G; Karapetis, C; Shannon, J; Goldstein, David B; Nayagam, S S; Blum, R; Chantrill, L; Simes, R J; Price, Timothy J |
| 6 | 1-Jun-2010 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. | Tebbutt, Niall C ; Wilson, Kate; Gebski, Val J; Cummins, Michelle M; Zannino, Diana; van Hazel, Guy A; Robinson, Bridget; Broad, Adam; Ganju, Vinod; Ackland, Stephen P; Forgeson, Garry; Cunningham, David; Saunders, Mark P; Stockler, Martin R; Chua, Yujo; Zalcberg, John R; Simes, R John; Price, Timothy J |
| 7 | 12-Jan-2010 | Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. | Tebbutt, Niall C ; Cummins, M M; Sourjina, T; Strickland, A; Van Hazel, G; Ganju, V; Gibbs, D; Stockler, M; Gebski, V; Zalcberg, John R |